– USA, CA – Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of former Celgene chairman and CEO, Mark Alles, to chair its board of directors, succeeding interim chair Garry Nicholson, who will remain on the board.
“Mark’s background, knowledge and experience align perfectly with our focus in oncology, the stage of our clinical assets and our aspirations for continued growth. On behalf of the entire board, we look forward to having Mark’s leadership as we focus on the advancement of our clinical stage drug candidates, build a pipeline for the future and move our lead asset closer to registration.” said CEO, Dr. Athena Countouriotis.
About Mark Alles
Mark Alles is an accomplished biopharmaceutical executive who led successful global oncology-focused organizations over his more than three-decade career, which includes driving growth and innovation during 15 years at Celgene until its $74-billion acquisition by Bristol Myers Squibb in 2019.
Mr. Alles brings deep operational, financial, business development, and commercial experience to the Turning Point board. He led the expansion of Celgene from a U.S.-based organization with less than 500 employees to a global company serving patients in more than 50 countries with 8,800 employees. Before being named chair in 2018 and CEO in 2016, Mr. Alles served as Celgene president and COO, EVP and Global Head of Hematology & Oncology, and chief commercial officer.
Before joining Celgene in 2004, he was VP of the U.S. Oncology business unit at Aventis Pharmaceuticals where he also served in other senior management roles during an 11-year period. He began his career in the biopharmaceutical industry at Bayer and worked at Centocor before its acquisition by Johnson & Johnson.
“This is an exciting time to join the Turning Point board, as the company plans for potential registration and commercialization of repotrectinib, advances a growing pipeline, and makes investments to build upon the strong foundation it has established over the past two years since the IPO,” said Mark Alles. “I look forward to working closely with such a distinguished board and management team.”
Mr. Alles is a member of the board of directors for Antengene Corporation and Syros Pharmaceuticals. He is a former board member of the Pharmaceutical Research and Manufacturers of America, the European Federation of Pharmaceutical Industries and Associations, and the Biotechnology Innovation Organization.
About Turning Point Therapeutics Inc.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R, and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor, which is being studied in a Phase 1/2 trial of previously treated patients with ALK-positive advanced or metastatic non-small cell lung cancer. Turning Point’s next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
For more information: https://tptherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
